Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

ANCA-Associated Vasculitis Pathogenesis & Treatment Updates

Thomas R. Collins  |  March 17, 2018

SAN DIEGO—At the 2017 ACR/ARHP Annual Meeting this past November, three researchers discussed the latest ANCA-associated vasculitis (AAV) research, including studies on AAV pathogenesis, therapies and remission maintenance. In the Philip Hench, MD, Memorial Lecture, J. Charles Jennette, MD, chair in pathology and laboratory medicine at the University of Carolina at Chapel Hill in Chapel…

Filed under:Meeting ReportsVasculitis Tagged with:ACR/ARHP Annual MeetingANCA-Associated VasculitisavacopanEGPAGPAmepolizumab

Rheumatologist Fellow Works in India Via ACR Exchange Program

Rajat Bhatt, MD  |  March 17, 2018

In November 2017, I went to Lucknow, India, where I would spend my time as an exchange fellow at the Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPIMS) as part of the ACR International Visiting Fellows Exchange Program. Where I Come From I completed my medical degree at Mahatma Gandhi Missions Medical College, Navi Mumbai…

Filed under:Career DevelopmentPractice Support Tagged with:International Visiting Fellows Exchange Program

The Why & What of the ACR's Clinical Practice Guidelines

The Why & What of the ACR’s Clinical Practice Guidelines

Ruth Jessen Hickman, MD  |  February 18, 2018

With the support of its membership, the ACR publishes clinical practice guidelines in multiple disease areas based on the best available clinical and scientific data. These aim to support health professionals treating rheumatology patients to give the best possible care. Like any set of medical guidelines, ACR guidelines are based on evidence of several different…

Filed under:Practice Support Tagged with:Clinical Practice GuidelinesThe American College of Rheumatology

Managing Myositis in 3 Different Scenarios

Susan Bernstein  |  February 18, 2018

SAN DIEGO—In Hot Topics in Myositis, a session held Nov. 7 at the 2017 ACR/ARHP Annual Meeting, rheumatologists discussed treating myositis patients in three different clinical scenarios: persistently elevated creatine kinase (CK), immune-mediated necrotizing myopathies and lung disease. Elevated CK Patients with persistently elevated levels of CK enzyme and normal muscle strength “may still have…

Filed under:ConditionsMeeting ReportsMyositisSoft Tissue Pain Tagged with:ACR/ARHP Annual MeetingcreatineInterstitial Lung Diseasemyositisnecrotizing myopathy

Rheumatoid Arthritis Research Advances

Larry Beresford  |  February 18, 2018

SAN DIEGO—In a roundup of current research in rheumatoid arthritis (RA) presented at the 2017 ACR/ARHP Annual Meeting Nov. 3–8, Mark C. Genovese, MD, professor of medicine in the Division of Immunology and Rheumatology at Stanford University, Palo Alto, Calif., urged his audience to reflect on the impact therapy advances have made on RA. “In…

Filed under:Meeting ReportsRheumatoid Arthritis Tagged with:ACR/ARHP Annual Meetingcombination therapyimagingInfection

New Rheumatology Disease Research & Advice

Thomas R. Collins  |  February 17, 2018

SAN DIEGO—Top researchers gathered for a review course at the start of the 2017 ACR/ARHP Annual Meeting in November to describe new research, their own treatment strategies and new ways of thinking about an array of rheumatic diseases. Here are the highlights: Raynaud’s & Other Digit Problems When a patient walks into your clinic with…

Filed under:Axial SpondyloarthritisMeeting ReportsOsteoarthritis and Bone DisordersRheumatoid ArthritisSystemic SclerosisVasculitis Tagged with:ACR/ARHP Annual Meetingadhesive capsulitisANCAaxial spondyloarthritis (SpA)diabetesDry eyeEthicslung diseasemeniscus surgeryOsteoarthritisRaynaud'sred eyeRheumatoid arthritisscleritisVasculitis

Etanercept Biosimilar Is Effective, Well-Tolerated for Rheumatoid Arthritis

David Douglas  |  February 16, 2018

NEW YORK (Reuters Health)—The biosimilar LBEC0101 is equivalent to etanercept (Enbrel) in treating patients with rheumatoid arthritis (RA) who respond inadequately to methotrexate, according to researchers from Korea and Japan. As Dr. Yeong-Wook Song tells Reuters Health by email, “LBEC0101 is comparable in efficacy, safety and immunogenicity profile to Enbrel.” The findings, he adds, could…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsetanerceptLBEC0101Rheumatoid Arthritis (RA)

How to Avoid Insurance Denials for Prescribing a Biologic Without MTX in Concert

From the College  |  February 15, 2018

The Insurance Subcommittee (ISC) of the ACR’s Committee on Rheumatologic Care (CORC) has recently received a number of reports from members regarding denials for biologics for patients not on methotrexate. To help avoid an often-lengthy appeals process, the ACR/ARHP recommends that members document a patient’s history of methotrexate intolerance or contraindication at every visit. What…

Filed under:From the CollegePractice Support Tagged with:BiologicsCommittee on Rheumatologic Care (CORC)Documentationinsurance denialsInsurance SubcommitteeMethotrexate

EU Approves Marketing for Ixekizumab in Adults with PsA

Michele B. Kaufman, PharmD, BCGP  |  February 7, 2018

In its second indication in the EU, ixekizumab has been approved by the European Commission to treat adults with active psoriatic arthritis…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:EuropeEuropean UnionixekizumabPsoriatic Arthritisskin

Higher Fracture Risk in Patients with Polymyalgia Rheumatica, Giant-Cell Arteritis

Will Boggs MD  |  January 24, 2018

NEW YORK (Reuters Health)—Patients with polymyalgia rheumatica (PMR) and giant-cell arteritis (GCA) have similarly increased risks of fracture, compared with the general population, researchers have found. “It is of surprise that patients with GCA have a similar fracture risk to those with PMR,” Dr. Zoe Paskins from Keele University, in Staffordshire, told Reuters Health by…

Filed under:ConditionsVasculitis Tagged with:fracture riskFracturesgiant cell arteritis (GCA)Polymyalgia Rheumatica

  • « Previous Page
  • 1
  • …
  • 52
  • 53
  • 54
  • 55
  • 56
  • …
  • 106
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences